Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Immunon Inc (IMNN) is a clinical-stage biotechnology pioneer developing DNA-based immunotherapies through its proprietary non-viral platform. This page serves as the definitive source for verified company updates, including clinical trial progress, regulatory milestones, and research breakthroughs.
Investors and researchers will find timely updates on key programs like the IMNN-001 ovarian cancer therapy (Phase II completed) and IMNN-101 COVID-19 booster candidate. Our curated news feed covers essential developments including partnership announcements, intellectual property updates, and peer-reviewed study publications.
Content is organized to highlight material events across three core areas: Clinical Trial Advancements, Regulatory Pathway Updates, and Technology Platform Innovations. Each update is vetted for relevance to stakeholders monitoring the company's progress in immuno-oncology and infectious disease applications.
Bookmark this page for structured access to Immunon's official communications, including SEC filings analysis and conference presentation summaries. Check regularly for developments in DNA-based therapeutic approaches that aim to redefine cancer treatment and vaccine development paradigms.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 trial of IMNN-001 at the International Gynecologic Cancer Society Annual Global Meeting, Nov 5-7, 2025 in Cape Town.
IMNN-001 is a DNA-mediated IL-12 plasmid delivered by nanoparticle (TheraPlas platform). The company treated the first patient in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The same TiP poster was also accepted at ESMO 2025.
Poster: "OVATION-3: A randomized phase III trial..." Presenting author: Douglas V. Faller, M.D., Ph.D. Poster number: TP014/#750.
IMUNON (Nasdaq: IMNN) will present new translational data from the Phase 2 OVATION 2 study of IMNN-001 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7, 2025 (Poster #1165, 12:15–1:45 PM ET).
IMNN-001 is a DNA-encoded IL-12 therapy using the TheraPlas® nanoparticle delivery platform. The company says OVATION 2 showed a clinically effective response in newly diagnosed advanced (stage IIIC/IV) epithelial ovarian cancer, including reported benefits in progression-free survival and overall survival, increases in key anti-cancer cytokines, and modulation of immune cell populations (CD8+ T cells, myeloid dendritic cells). IMNN-001 is advancing into the pivotal OVATION 3 Phase 3 trial per plan.
IMUNON (Nasdaq: IMNN) will host an R&D Day for investors on November 10, 2025 at the Harvard Club in New York City, starting at 8:00 a.m. ET.
The program will provide updates on the pivotal Phase 3 OVATION 3 study of IMNN-001 and a Phase 2 MRD trial, featuring presentations from ovarian cancer clinical leaders, Phase 3 investigators, statistical experts and IMUNON management. Presentations will cover safety, translational insights, trial design probability of success, and an OVATION 3 trial update, followed by a live Q&A and networking.
IMUNON (Nasdaq: IMNN) announced oral presentations of PlaCCine® DNA vaccine proof-of-concept data and IMNN-101 clinical results at two vaccine conferences: Oct 23, 2025 (International Vaccines Congress, Orlando) and Nov 6, 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN reported positive six-month Phase 1 data showing better durability versus mRNA after a single dose targeting SARS-CoV-2 Omicron XBB1.5, with up to a 3-fold median increase in serum neutralizing antibody titers at six months and stronger responses in the 2.0 mg and 1.0 mg cohorts. IMNN-101 was safe and well tolerated with no serious adverse effects. The company is seeking strategic partners to advance PlaCCine commercialization, highlighting durability, temperature stability, and scalable manufacturing.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 study of IMNN-001 at the European Society for Medical Oncology (ESMO) Congress, October 17–21, 2025 in Berlin.
IMNN-001 is an IL-12 DNA plasmid delivered in a nanoparticle to elicit local tumor immune responses. The company announced the first patient treated in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The poster (No. 1234eTiP) will be presented by Dr. Premal H. Thaker and posted on IMUNON’s Scientific Presentations page after the conference.
IMUNON (NASDAQ: IMNN) presented promising new translational data from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study, involving 112 participants, demonstrated significant improvements in the tumor micro-environment (TME) through the local administration of IL-12 immunotherapy.
Key findings showed a positive TME shift in the majority of participants, with 50-80% of samples showing increased anti-tumor cells and 65-80% showing decreased immunosuppressive markers. The therapy effectively transformed "cold" tumors to "hot" by activating both innate and adaptive immune systems, while maintaining a favorable safety profile.
The company has initiated its pivotal Phase 3 OVATION 3 Study with four active trial sites currently enrolling patients.
IMUNON (NASDAQ: IMNN) announced it will present new translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the AACR Special Conference in Cancer Research. IMNN-001 is a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer currently in Phase 3 development.
The therapy utilizes IMUNON's TheraPlas® technology platform, incorporating an IL-12 DNA plasmid vector into a nanoparticle delivery system. It has demonstrated clinical effectiveness in advanced ovarian cancer, showing benefits in both progression-free survival and overall survival when combined with standard chemotherapy.
The presentation, titled "IMNN-001, an IL-12 gene therapy, added to Neo/Adjuvant chemotherapy safely turns the tumor microenvironment cold-to-hot in newly diagnosed epithelial ovarian cancer (EOC)," will be delivered by Dr. Douglas V. Faller, Chief Medical Officer, on September 20, 2025.
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company will provide a pre-recorded presentation that will be available on demand starting September 5, 2025, at 7:00 a.m. ET. IMUNON's management team will conduct in-person one-on-one meetings with investors from September 8-10, 2025. The presentation webcast will remain accessible for 90 days through the company's website.
IMUNON (Nasdaq: IMNN) has successfully regained compliance with Nasdaq's minimum bid price listing requirement, ensuring continued trading on The Nasdaq Capital Market. The company recently distributed a 15% stock dividend to shareholders of record as of August 7, 2025.
The announcement comes amid positive developments in IMUNON's clinical pipeline, including successful Phase 2 OVATION 2 trial results for IMNN-001, their DNA-based immunotherapy for advanced ovarian cancer treatment. The company has initiated the Phase 3 OVATION 3 trial in North America while advancing their TheraPlas® technology platform.
IMUNON (NASDAQ: IMNN) provided key updates from its Q2 2025 conference call, highlighting significant progress in its Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. The company has successfully enrolled and treated its first patient, achieving a rapid launch in just 15 weeks compared to the industry average of 28 weeks.
The company announced a 15% stock dividend for shareholders of record as of August 7, 2025. IMUNON has strengthened its financial position by raising over $3 million through warrant exercises and ATM sales. The company expects to meet Nasdaq's compliance requirements, including the Bid Price requirement, by August 8, 2025.
The Phase 3 trial features a flexible enrollment strategy starting with 250 HRD-positive patients, reducing costs by approximately 40%, with potential expansion to 500 patients. The company maintains efficient in-house manufacturing for IMNN-001, significantly reducing costs compared to outsourcing.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
